Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based compensation (Tables)

Stock-based compensation (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards Under the Pieris Plan

Total stock-based compensation expense was recorded to operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows:


	Three months ended September 30,				Nine months ended September 30,
	2016		2015		2016		2015
Research and Development	$	142,254	$	88,176	$	444,193	$	217,766
General and administrative		303,859		249,613		982,148		605,398

Total stock-option expense	$	446,113	$	337,789	$	1,426,341	$	823,164

Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted

The weighted-average fair value of the options granted during the three and nine months ended September 30, 2015 was $1.95 and $1.94, respectively. The calculation was based on the following assumptions:


	Three months ended September 30,						Nine months ended September 30,
	2016			2015			2016			2015
Dividend yield		0.0	%		0.0	%		0.0	%		0.0	%
Expected volatility		74.9% - 75.12	%		72.65% - 73.43	%		74.90% - 76.00	%		72.65% - 75.07	%
Weighted average risk-free interest rate		1.25% - 1.35	%		1.69% - 1.89	%		1.13% - 1.61	%		1.49% - 1.89	%
Expected term		5.0 - 5.7 years			5.0 - 6.1 years			5.0 - 5.7 years			5.0 - 6.1 years